PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex. PURPOSE 2 FAQs · Purpose 3 · Study Locations · About the Study

13 нояб. 2024 г. · PURPOSE 2 is the second pivotal Phase 3 trial to demonstrate superior efficacy for twice-yearly lenacapavir for the investigational use of HIV ...

26 сент. 2024 г. · The PURPOSE 2 trial reported a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not ...

The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir and background ...

PURPOSE 2 is evaluating an investigational drug, lenacapavir, and enrolled cisgender men, transgender women, transgender men, and gender non-binary individuals ... Purpose 2 · PURPOSE 2 FAQs · Purpose 1 · Purpose 3

12 сент. 2024 г. · Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second ...

Lenacapavir, given as a 6-monthly subcutaneous injection after a short oral lead-in, was also significantly more effective in PURPOSE 2 than the control arm ...

PURPOSE 2 is a study to find out if long-acting, injectable (given as a shot) lenacapavir for PrEP is safe and acceptable for adolescents.

7 окт. 2024 г. · New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024.

13 нояб. 2024 г. · Those previously reported data showed that lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV), with two ...